Historical Review Describing Hemorrhage and Thrombosis

Check with your local medical library for Franchini M, Zani M, Focosi D. Human evolution: between hemorrhage and thrombosis. Semin Thromb Hemost. 2026. doi: 10.1055/a-2905-4308. PMID: 42398954. Abstract The human coagulation system has resulted from thousands of years of evolutionary pressure, finely balancing the competing risks of lethal hemorrhage and catastrophic thrombosis. There are several […]

Comments (0)

Bleeding Disorders

Oct 28 2026

george

Illustrated Review: History of Anticoagulant Pharmacology

Here’s an open-access illustrated review that includes FXI and FXII inhibitors currently in development: Wichaiyo S. Pharmacology of anticoagulants: from heparin to novel target-specific agents. J Thromb Haemost. 2026:S1538-7836(26)00486-1. doi: 10.1016/j.jtha.2026.08.001. PMID: 42567362. Abstract Anticoagulants are the drugs of choice for the management of various thromboembolic disorders affecting both arteries and veins. This review delineates […]

Comments (0)

Anticoagulant Therapy

Oct 27 2026

george

Laboratory Diagnostics for Thrombosis and Hemostasis Testing

Here is a detailed introduction to the fifth “Seminars in Hemostasis and Thrombosis” issue devoted to laboratory testing: Smock KJ, Moffat KA. Laboratory diagnostics for thrombosis and hemostasis testing-Part V. Semin Thromb Hemost. 2026;52(8):887-888. doi: 10.1055/a-2912-7667. PMID: 42913665. The 14 citations are available as open-access articles.

Events

A Meta-Analysis: Microplastics, Nanoplastics, and Thrombogenesis

Thanks to Dr. Emmanuel Favaloro for featuring this provocative open-access meta-analysis connecting microplastics and hemostasis. Balwan R, Hew YY, Gurumurthy G, et al. Microplastics, nanoplastics, and thrombogenesis. Res Pract Thromb Haemost. 2026;10(7):106931. doi: 10.1016/j.rpth.2026.106931. PMID: 42894845; PMCID: PMC13677222. Abstract Micro- and nanoplastics (MNPs) are produced through mechanical, chemical, and ultraviolet-mediated degradation of plastics and may […]

Thrombophilia

Summary–Current Hemophilia Therapy: FVIII Bypassing and Rebalancing

Click for an illustrated outline in Hemophilia Today, “The Rebalanced Patient: New Therapies and New Thrombotic Risks in Hemophilia.” Introduction For decades, the central therapeutic principle in hemophilia was straightforward: replace what was missing. In hemophilia A, this meant replacing FVIII; in hemophilia B, FIX. Prophylactic factor replacement transformed hemophilia from a condition dominated by recurrent […]

Bleeding Disorders

Can We Confirm a DOAC Overdose?

Here’s a provocative question from Sacha N. Uljon, MD, PhD, Medical Director, Massachusetts General Brigham Special Coagulation Integrated Laboratory Service: Hello, this post is about lab findings in apixaban overdose. We have now seen two suicide attempts involving apixaban. There was no clot at all on the PT/PTT (Werfen/Hemosil), so the anti-Xa level can’t be […]

Comments (0)

Anticoagulant Therapy

Oct 20 2026

george

A World Thrombosis Day Post: Blood Clots Can Affect Anyone

Dr. Ali Sadeghi-Khomami: On World Thrombosis Day (13 October), a simple reminder: blood clots can affect anyone, and where a clot forms can have very different consequences. Let’s continue raising awareness about thrombosis, its risk factors, and the importance of early recognition. Know your risk. Recognize the signs. Take action.

Thrombophilia

Reduced-dose DOACs in Cancer-associated Thrombosis

Click for this open-access retrospective cohort study reporting the safety and efficacy outcomes for reduced-dose DOACS: Santini P, Santagata D, Mosoni C, et al. Full- versus reduced-dose direct oral anticoagulants for extended treatment of cancer-associated thrombosis: a multicenter retrospective cohort study. Semin Thromb Hemost. 2026. doi: 10.1055/a-2904-5824. PMID: 42379243. Abstract Extended anticoagulation is recommended in […]

Comments (0)

Anticoagulant Therapy

Oct 20 2026

george

What is Fibrinogen Longmont?

Click here for an open-access case report of a variant fibrinogen: Ma C, Li X, Yin D, et al. Rapid laboratory identification of fibrinogen Longmont: a case report and literature review. Front Med (Lausanne). 2026;13:1781076. doi: 10.3389/fmed.2026.1781076. PMID: 42440479; PMCID: PMC13333428. Abstract This study reports a case of a patient with unstable angina with abnormally […]

Bleeding Disorders

Heparin Effect on Chemiluminescence HIT Testing

Check with your local library for this HIT testing report: Vong R, Pasalic L, Donikian D, Brighton T, Favaloro EJ. Effect of heparin on immunological heparin-induced thrombocytopenia-IgG chemiluminescence testing. Blood Coagul Fibrinolysis. 20261;37(7):329-335. doi: 10.1097/MBC.0000000000001456. PMID: 42615582. Heparin-induced thrombocytopenia (HIT) requires clinical evaluation and laboratory testing using immunological assays with confirmation by functional assays such […]

Comments (0)

Anticoagulant Therapy

All Posts

Historical Review Describing Hemorrhage and Thrombosis

Illustrated Review: History of Anticoagulant Pharmacology

Laboratory Diagnostics for Thrombosis and Hemostasis Testing

A Meta-Analysis: Microplastics, Nanoplastics, and Thrombogenesis

Summary–Current Hemophilia Therapy: FVIII Bypassing and Rebalancing

Can We Confirm a DOAC Overdose?

A World Thrombosis Day Post: Blood Clots Can Affect Anyone

Reduced-dose DOACs in Cancer-associated Thrombosis

What is Fibrinogen Longmont?

Heparin Effect on Chemiluminescence HIT Testing

George Fritsma MS MLS

Cheat Sheets from George

Questions or Comments?

Quick Question